Rowasa belongs to a group of medications called aminosalicylates. It is thought that the drug works by inhibiting the production of inflammatory chemicals in the lining of the
colon. Rowasa decreases the production of prostaglandins and leukotrienes, chemicals that lead to the inflammation of
ulcerative colitis.
Rowasa has not been approved for the treatment of ulcerative colitis in children. Be sure to talk with your healthcare provider about the risks and benefits of using Rowasa for children.
On occasion, your healthcare provider may recommend Rowasa for treating something other than the conditions listed above. This is called an "
off-label" use. Among these potential off-label Rowasa uses is the treatment of
Crohn's disease.
Previous
Add this article to your Favorites
Email this article
Print